Alergix MR10 mg

Alergix MR is a second-generation (non-sedating) H1-antihistamine used for the symptomatic relief of allergic conditions. Its evidence-based uses include:

• Established/guideline-supported use: Symptomatic treatment of seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis, including relief of sneezing, rhinorrhea, nasal itching, and ocular itching associated with these conditions.
• Established/guideline-supported use: Symptomatic relief of chronic idiopathic urticaria, including reduction of pruritus (itching) and number/size of wheals.

Alergix MR is a symptomatic treatment only; it does not address the underlying cause of allergic disease and is not indicated for the treatment of acute anaphylaxis or bronchospasm.

Each film-coated tablet typically contains Mizolastine 10 mg as the active ingredient, along with pharmaceutically approved excipients such as fillers, binders, and coating agents. Exact composition may vary by manufacturer; refer to the specific product label for full excipient details.

Alergix MR is a piperidine-benzimidazole derivative that acts as a selective, long-acting, non-sedating antagonist of peripheral histamine H1-receptors. It is used in the symptomatic management of allergic rhinitis and chronic urticaria. Unlike first-generation antihistamines, Alergix MR penetrates the blood-brain barrier only minimally, which accounts for its comparatively low sedative potential, although it is not entirely free of central nervous system effects in all patients.

Alergix MR is formulated as an oral tablet taken once daily. It is marketed in several countries (notably parts of Europe) under various trade names; its availability varies by market, and local availability in Bangladesh should be confirmed with a pharmacist or physician before prescribing or dispensing.

Alergix MR belongs to the therapeutic class of second-generation (non-sedating) H1-antihistamines, used in the management of allergic rhinitis and urticaria.

Mechanism of Action

Mizolastine is a selective and competitive antagonist of peripheral histamine H1-receptors. By blocking H1-receptors, it prevents histamine-mediated vasodilation, increased vascular permeability, and stimulation of sensory nerve endings that produce the classic symptoms of allergic rhinitis and urticaria (sneezing, rhinorrhea, pruritus, and wheal-and-flare reactions). Mizolastine also has secondary anti-allergic properties, including inhibition of mast cell mediator release and reduction of eosinophil chemotaxis and activation, which may contribute to its overall anti-allergic effect beyond simple H1-blockade.

Pharmacokinetics

Mizolastine is rapidly absorbed after oral administration, with clinical effect typically evident within about an hour and lasting through a 24-hour dosing interval, supporting once-daily dosing. It undergoes hepatic metabolism, partly via the CYP3A4 pathway, which underlies its clinically important interaction with potent CYP3A4 inhibitors (see Interactions). Because of its limited penetration across the blood-brain barrier, central nervous system (sedative) effects are less prominent than with first-generation antihistamines, though individual sensitivity varies and mild drowsiness can still occur.

Alergix MR should be swallowed whole with a glass of water, at approximately the same time each day, preferably before the evening meal. It can be taken with or without food, but consistency in timing helps maintain a steady therapeutic effect. Do not exceed the dose or frequency prescribed by the physician.

Clinically significant interactions with Alergix MR arise mainly from its potential to prolong the cardiac QT interval when combined with certain drugs:

• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, and macrolide antibiotics such as erythromycin): these raise plasma concentrations of Alergix MR through inhibition of its hepatic metabolism, increasing the risk of QT prolongation and cardiac arrhythmia. Concurrent use is contraindicated (see Contraindications).
• Other QT-interval-prolonging drugs (e.g., certain antiarrhythmics, some antipsychotics, and certain other antimicrobials): concurrent use with Alergix MR is contraindicated due to additive risk of serious ventricular arrhythmia, including torsades de pointes.
• Drugs or conditions causing electrolyte disturbances (e.g., potassium-wasting diuretics leading to hypokalemia): may indirectly increase arrhythmia risk when combined with Alergix MR; use with caution and correct electrolyte abnormalities before starting therapy.
• Central nervous system depressants/alcohol: although Alergix MR has low sedative potential, caution is advised with concomitant alcohol or sedating medications, as some individuals may experience additive drowsiness.

Patients should seek prompt medical attention for palpitations, fainting, or signs of an allergic reaction while taking Alergix MR.

Pregnancy: Data on the use of Alergix MR in pregnant women are insufficient to establish safety. As a precaution, Alergix MR should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not known whether Alergix MR is excreted in human breast milk. Because of the theoretical risk to the nursing infant, breastfeeding is not recommended during treatment with Alergix MR unless a physician determines the benefit outweighs the risk.

Use Alergix MR with caution in the following situations:

• Cardiac disease: patients with underlying heart disease, bradycardia, or a family history of QT prolongation warrant caution and physician assessment before use.
• Electrolyte disturbances: correct hypokalemia or other electrolyte imbalances before starting therapy, as these increase the risk of QT-related arrhythmia (see Interactions).
• Elderly patients: may be more susceptible to cardiac conduction effects; use with caution.
• Hepatic or renal impairment: use with caution in mild impairment and avoid in significant hepatic impairment (see Contraindications).
• CNS effects: although less sedating than first-generation antihistamines, Alergix MR is not entirely free of central nervous system effects; patients should assess their individual response before driving or operating machinery.
• Do not exceed the recommended dose, and avoid combining Alergix MR with the drugs listed under Contraindications and Interactions.

Overdose with Alergix MR may increase the risk of QT-interval prolongation and cardiac arrhythmia. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Management is supportive and may include cardiac (ECG) monitoring; there is no specific antidote. Do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose adjustment is generally required for Alergix MR, but increased caution is warranted due to greater susceptibility to cardiac conduction effects.

Renal impairment: Limited data are available; use Alergix MR with caution, especially in moderate-to-severe renal impairment.

Hepatic impairment: Alergix MR is contraindicated in significant/severe hepatic impairment; use with caution under medical supervision if impairment is mild.

Pediatric patients: Safety and efficacy of Alergix MR have not been established in children under 12 years of age (see Pediatric Uses).

For seasonal allergic rhinitis, Alergix MR is typically used for the duration of allergen exposure/symptom season, as directed by a physician. For perennial allergic rhinitis and chronic idiopathic urticaria, treatment may continue longer term under medical supervision, with periodic reassessment (e.g., every few months) to confirm continued need and to monitor for adverse effects, particularly cardiac safety parameters where relevant.

Mizolastine is classified under: Antihistamines (non-sedating, second-generation); H1-receptor antagonists.

Mizolastine works by selectively and competitively blocking peripheral histamine H1-receptors, thereby preventing histamine from producing the vasodilation, capillary permeability changes, and sensory nerve stimulation that underlie allergic symptoms such as sneezing, nasal congestion, itching, and wheal formation. It additionally suppresses mast cell mediator release and eosinophil activity, contributing an anti-inflammatory component to its antiallergic effect.

The safety and efficacy of Alergix MR have not been established in children under 12 years of age; it should not be used in this age group. In adolescents 12 years of age and older, Alergix MR may be used at the same dose as adults (10 mg once daily) for approved indications, under medical supervision.